Landscape Capital Management L.L.C. Raises Holdings in Eli Lilly and Company (NYSE:LLY)

Landscape Capital Management L.L.C. increased its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 200.9% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 4,919 shares of the company's stock after buying an additional 3,284 shares during the period. Landscape Capital Management L.L.C.'s holdings in Eli Lilly and Company were worth $3,797,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in LLY. PAX Financial Group LLC grew its position in shares of Eli Lilly and Company by 19.6% during the 4th quarter. PAX Financial Group LLC now owns 1,020 shares of the company's stock valued at $787,000 after acquiring an additional 167 shares during the period. Astra Wealth Partners LLC purchased a new position in Eli Lilly and Company in the fourth quarter valued at approximately $202,000. Wescott Financial Advisory Group LLC grew its holdings in Eli Lilly and Company by 1.1% during the fourth quarter. Wescott Financial Advisory Group LLC now owns 9,381 shares of the company's stock valued at $7,242,000 after purchasing an additional 98 shares during the period. Thoroughbred Financial Services LLC increased its position in Eli Lilly and Company by 7.7% in the fourth quarter. Thoroughbred Financial Services LLC now owns 20,792 shares of the company's stock worth $16,051,000 after buying an additional 1,487 shares during the last quarter. Finally, Resolute Advisors LLC purchased a new stake in Eli Lilly and Company in the fourth quarter worth $279,000. Institutional investors own 82.53% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. Berenberg Bank set a $970.00 price target on Eli Lilly and Company in a research report on Thursday, January 16th. Wells Fargo & Company upped their price objective on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Citigroup reduced their target price on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a "buy" rating for the company in a research note on Tuesday, January 28th. Truist Financial upped their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the company a "buy" rating in a research note on Monday, February 3rd. Finally, Leerink Partners set a $950.00 price objective on shares of Eli Lilly and Company in a research note on Friday, January 17th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average price target of $1,009.72.

Remove Ads

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the company's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Price Performance

Shares of NYSE LLY traded down $51.53 during mid-day trading on Friday, reaching $737.56. 5,289,016 shares of the company were exchanged, compared to its average volume of 3,322,098. Eli Lilly and Company has a 52 week low of $706.96 and a 52 week high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The stock has a market capitalization of $699.33 billion, a PE ratio of 62.99, a PEG ratio of 1.40 and a beta of 0.34. The company's 50 day moving average price is $848.36 and its 200 day moving average price is $832.44.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts' consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company announced that its Board of Directors has authorized a share buyback program on Monday, December 9th that allows the company to repurchase $15.00 billion in shares. This repurchase authorization allows the company to purchase up to 2% of its stock through open market purchases. Stock repurchase programs are often an indication that the company's board believes its stock is undervalued.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.